*Disclaimer

PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX: PAR)

๐Ÿ”— ๐Ÿ“„ ๐Ÿ“ˆ

PAR: PAR Reports Phase 3 Clinical Trial Update

PARADIGM BIOPHARMACEUTICALS LIMITED..

2023-07-04 08:19:00

PAR: Primary and Secondary endpoints met in MPS I Trial

PARADIGM BIOPHARMACEUTICALS LIMITED..

2023-06-06 12:28:00

PAR: iPPS shows 3-year equivalent durability in OA Canine Study

PARADIGM BIOPHARMACEUTICALS LIMITED..

2023-06-01 08:21:00

PAR: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study

PARADIGM BIOPHARMACEUTICALS LIMITED..

2023-04-04 09:29:00